Clinical trial
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
NCT00113321 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00113321 |
|---|---|
| Title | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure |
| Official title | Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eisai Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia |
| Intervention type | Drug |
| Interventions | Decitabine |
| Enrollment | 16 |
| Start date | Mar 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jun 8, 2005 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: